Radioligand therapeutics, also known as radiopharmaceuticals, which show antitumor effects, has seen rapid development over the past decade. Although some therapies are already approved for human use, many more are in the clinical trial and will enter clinical practice in the next 2-7 years, potentially introducing new therapeutic choices for patients. Despite this innovation, several challenges remain, including supply chain, logistics, regulatory issues, and education and training. 

The current market for radioligand therapy is majorly dominated by manufacturers such as Novartis AG, Pfizer Inc, Johnson Johnson Services, Inc, Telix Pharmaceuticals, Lantheus Holdings Inc., (Progenics Pharmaceuticals), Molecular Partners AG, Clovis Oncology Inc., Fusion Pharma, Point Biopharma, Precirix, ITM Isotope Technologies Munich SE, Curium Pharma, and RadioMedix. 

The global radioligand therapy market was valued at $9.75 billion in 2020 and is projected to reach $16.65 billion by 2031, reveals the premium market intelligence study by BIS Research. The study also highlights that the market is set to witness a CAGR of 4.67% during the forecast period 2021-2031.

In the comprehensive study of the global radioligand therapy market, BIS Research extensively covers the following:

• Market numbers on micro-segments influencing the market
• Market share analysis of key market players
• Growth share analysis of companies
• Impact of COVID-19 on the global radioligand therapy market
• Growth analysis by indication, product, biomarker, and region
• Detailed company and product profiling for 16 companies
• Pipeline analysis for potential pipeline drugs
• Market scenario for radioligand therapy marketed products and potential pipeline products
• Drivers promoting the growth of the market
• Emerging opportunities in the radioligand therapy market

Besides these parameters, the study also encompasses the market growth drivers, market restraining factors, opportunities, competition mapping, and segmental analysis.

BIS Research study indicates that the growing prevalence of cancer, strategic initiatives by key market players, and the rise in microbial sequencing are the major factors anticipated to contribute to the growth of the global radioligand therapy market.

The detailed study is a compilation of 07 market data tables and 138 figures spread through 182 pages and in-depth TOC on “Global Radioligand Therapy Market – Analysis and Forecast, 2021-2031”

USP of the Report

This extensive report can help in the following ways:

• Aids in product development
• Helps in targeting a segment for launching and approval of a new product
• Offers go-to-market strategies for the different product categories
• Supports diversifying the product portfolio based on unmet needs
• Helps in analyzing technological substitutes and compares the specification
• Helps to adjust the pricing of upcoming products
• Assists in exploring the newer applications
• Supports in analyzing the competitors’ funding scenario

 COVID-19 Impact on Global Radioligand Therapy Market

The global spread of COVID-19, caused by the novel coronavirus SARS-CoV-2, has resulted in a continuing pandemic threat to global health. Nuclear medicine techniques can be used for functional imaging of pathophysiological processes at the cellular level and for treatment approaches based on targeted delivery of therapeutic radionuclides. Ongoing development of radiolabeling methods has significantly improved the accessibility of radiopharmaceutical products for targeted radionuclide therapy, but their use for biosafety threats such as SARS-CoV-2 is restricted by the contagious nature of these agents.

Moreover, radioligand therapies rely on complex supply chains and advanced logistics. The lockdowns imposed by most countries and the closure of borders have generated shortages of radionuclides and other essential raw material supplies in many countries

Analyst’s Take on the Market:

According to Nitish Kumar Singh, Principal Analyst – BIS Research, “The reason for market growth can be attributed to the increasing prevalence of cancer, the rising strategic initiatives taken by key market players, and rising in clinical research activity. Biomarkers such as prostate-specific membrane antigen, Ki 67 Expression and Grading, Cytochrome P450 17a1 contain valuable information. Deciphering the expanding radiopharmaceuticals coverage provides an opportunity to develop radioligand therapy for the treatment of cancer, mainly prostate cancer.” Moreover, the use of radioligand to generate gastrin-releasing peptide receptors represents an emerging strategy in the drug discovery field. The approach offers improved affinity, stability, and cellular penetration. A captivating future of drug discovery is envisaged by the potential of potent breakthrough drugs that are no longer limited to extracellular or receptor targets. The utilization of radiopharmaceuticals for the design of gastrin-releasing radioligand peptide receptors can be a prominent and significantly lucrative approach to result in successful radioligand drug discovery.”

Who should buy this report?

• Manufacturers of radioligand therapy-approved products and potential pipeline products
• Pharmaceutical and biotechnology companies
• Research and academic institutions

Key Questions Answered in the Report:

• How is radioligand therapy revolutionizing oncology?
• What are the major market drivers, challenges, and opportunities in the global radioligand therapy market?
• What are the underlying structures resulting in the emerging trends within the global radioligand therapy market?
• How is the COVID-19 pandemic impacting the global radioligand therapy ecosystem?
• What are the key development strategies that the major players are implementing in order to sustain themselves in the competitive market?
• What are the key regulatory implications in developed and developing regions pertaining to the use of radioligand-targeted therapies?
• What are the potential entry barriers expected to be faced by the companies willing to enter a particular region?
• How is each market segment expected to grow during the forecast period 2021-2031, and what is the anticipated revenue to be generated by each segment? Following are the segments:
o Products (Approved Products and Potential Pipeline)
o Indication (Prostate Cancer, Neuroendocrine Tumor (NETs), and Others)
o Biomarker (Prostate-Specific Membrane Antigen, Ki 67 Expression and Grading, Cytochrome P450 17A1 Inhibitor)
o Region (North America, Europe, Asia-Pacific, and Rest-of-the-World)
• What are the growth opportunities for the radioligand therapy companies in the region of their operation?
• Who are the leading players with significant offerings in the global radioligand therapy market?
• Which companies are expected to be highly disruptive in the future, and why?

Get FREE Sample Report -  https://bisresearch.com/requestsample?id=1280type=download

The scope of the report exclusively covers manufacturers offering proprietary radioligand therapy for target indications such as prostate cancer and neuroendocrine tumors. The study considers products based on various radioisotopes underlying applications in oncology to detect biomarkers and treatment of cancers. Moreover, the study considers the generics sales of Zytiga.